CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Atazanavir

阿扎那韦 杂质对照品Atazanavir Impurities

EP51 个杂质条目51 impurity entries

本页汇总 阿扎那韦 的 51 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 51 impurity reference standards of Atazanavir with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 阿扎那韦(Atazanavir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesSimultaneous Determination of Impurities of Atazanavir and Ritonavir in Tablet Dosage Form by Using Reversed-Phase Ultra Performance Liquid Chromatographic Method
    Journal of chromatographic science · 2018 · Mantripragada MKVVN et al.  ·  PMID 29300835  ·  DOI
  2. 杂质研究Impurity studiesDetermination of genotoxic impurity in atazanavir sulphate drug substance by LC-MS
    Journal of pharmaceutical and biomedical analysis · 2017 · K GB et al.  ·  PMID 27723524  ·  DOI
  3. 杂质研究Impurity studiesGradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate
    Journal of pharmaceutical and biomedical analysis · 2011 · Chitturi SR et al.  ·  PMID 21316175  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and validation of a UPLC-MS method for determination of atazanavir sulfate by the "analytical quality by design" approach
    Acta pharmaceutica (Zagreb, Croatia) · 2020 · Saha C et al.  ·  PMID 31677371  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisA three step continuous flow synthesis of the biaryl unit of the HIV protease inhibitor Atazanavir
    Organic & biomolecular chemistry · 2013 · Dalla-Vechia L et al.  ·  PMID 24175328  ·  DOI

阿扎那韦 —— 原料药与杂质对照品Atazanavir — drug substance & impurities

共 52 个条目(含原料药本体)52 items incl. the drug substance
Atazanavir structure
EP原料药 APIAPI
阿扎那韦Atazanavir
Atazanavir
CAS No.198904-31-3
Chemical FormulaC38H52N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir EP Impurity A (Pyridinyl Benzoic Acid) structure
EPA
阿扎那韦杂质11 (阿扎那韦EP杂质A)Atazanavir EP Impurity A (Pyridinyl Benzoic Acid)
Atazanavir EP Impurity A (Pyridinyl Benzoic Acid)
CAS No.4385-62-0
Chemical FormulaC12H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir EP Impurity B (Pyridinyl Benzaldehyde) structure
EPB
阿扎那韦杂质12 (阿扎那韦EP杂质B)Atazanavir EP Impurity B (Pyridinyl Benzaldehyde)
Atazanavir EP Impurity B (Pyridinyl Benzaldehyde)
CAS No.127406-56-8
Chemical FormulaC12H9NO
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir EP Impurity C structure
EPC
阿扎那韦杂质13 (阿扎那韦EP杂质C)Atazanavir EP Impurity C
Atazanavir EP Impurity C
CAS No.1192224-24-0
Chemical FormulaC26H43N5O7
Purity>95%询价On request
10mg25mg50mg100mg
N-Nitroso Atazanavir EP Impurity C structure
EPC
N-Nitroso Atazanavir EP Impurity C
CAS No.—
Chemical FormulaC26H42N6O8
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir EP Impurity E (Atazanavir S,R,S,S-Diastereomer) structure
EPE
阿扎那韦杂质7 (阿扎那韦EP杂质E)Atazanavir EP Impurity E (Atazanavir S,R,S,S-Diastereomer)
Atazanavir EP Impurity E (Atazanavir S,R,S,S-Diastereomer)
CAS No.1292296-09-3
Chemical FormulaC38H52N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir EP Impurity F (Atazanavir R,S,S,S-Diastereomer) structure
EPF
阿扎那韦杂质1 (阿扎那韦EP杂质F) ((3R,8S,9S,12S)-阿扎那韦)Atazanavir EP Impurity F (Atazanavir R,S,S,S-Diastereomer)
Atazanavir EP Impurity F (Atazanavir R,S,S,S-Diastereomer)
CAS No.1332981-14-2
Chemical FormulaC38H52N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir EP Impurity G (Atazanavir S,S,S,R-Diastereomer) structure
EPG
阿扎那韦杂质2 (阿扎那韦EP杂质G) ((3S,8S,9S,12R)-阿扎那韦)Atazanavir EP Impurity G (Atazanavir S,S,S,R-Diastereomer)
Atazanavir EP Impurity G (Atazanavir S,S,S,R-Diastereomer)
CAS No.1332981-16-4
Chemical FormulaC38H52N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir EP Impurity H (Atazanavir S,R,R,S-Diastereomer) structure
EPH
阿扎那韦EP杂质HAtazanavir EP Impurity H (Atazanavir S,R,R,S-Diastereomer)
Atazanavir EP Impurity H (Atazanavir S,R,R,S-Diastereomer)
CAS No.—
Chemical FormulaC38H52N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir EP Impurity J (Atazanavir Di-tert-butyl Analog) structure
EPJ
阿扎那韦杂质16 (阿扎那韦EP杂质J)Atazanavir EP Impurity J (Atazanavir Di-tert-butyl Analog)
Atazanavir EP Impurity J (Atazanavir Di-tert-butyl Analog)
CAS No.198904-86-8
Chemical FormulaC32H42N4O5
Purity>95%询价On request
10mg25mg50mg100mg
(R)-Atazanavir EP Impurity K ((R)-Atazanavir USP Related Compound A) structure
EPK
阿扎那韦EP杂质K(R)-Atazanavir EP Impurity K ((R)-Atazanavir USP Related Compound A)
(R)-Atazanavir EP Impurity K ((R)-Atazanavir USP Related Compound A)
CAS No.1191091-65-2
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir EP Impurity K (Atazanavir USP Related Compound A) structure
EPK
阿扎那韦杂质15 (阿扎那韦EP杂质K)Atazanavir EP Impurity K (Atazanavir USP Related Compound A)
Atazanavir EP Impurity K (Atazanavir USP Related Compound A)
CAS No.162537-11-3
Chemical FormulaC8H15NO4
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir S,S,R,S-Diastereomer structure
—
阿扎那韦杂质53Atazanavir S,S,R,S-Diastereomer
Atazanavir S,S,R,S-Diastereomer
CAS No.1292296-10-6
Chemical FormulaC38H52N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir R,S,S,R-Diastereomer structure
—
阿扎那韦杂质4((3R,8S,9S,12R)-阿扎那韦)Atazanavir R,S,S,R-Diastereomer
Atazanavir R,S,S,R-Diastereomer
CAS No.1292296-11-7
Chemical FormulaC38H52N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Hydrazine Analog TriHCl structure
—
阿扎那韦杂质10Atazanavir Hydrazine Analog TriHCl
Atazanavir Hydrazine Analog TriHCl
CAS No.198904-87-9
Chemical FormulaC22H26N4O
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Benzylidenehydrazine Carbamate structure
—
Atazanavir Benzylidenehydrazine Carbamate
CAS No.3068810-09-0
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Erythro-N-Boc-D-phenylalanine Epoxide 98818-34-9 structure
—
Erythro-N-Boc-D-phenylalanine Epoxide
CAS No.98818-34-9
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Benzylidenehydrazine Analogue structure
—
Atazanavir Benzylidenehydrazine Analogue
CAS No.—
Chemical FormulaC34H33N5O
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impuirty 5 structure
—
Atazanavir Impuirty 5
CAS No.—
Chemical FormulaC24H29NO11
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir R,R,R,R-diastereomer structure
—
Atazanavir R,R,R,R-diastereomer
CAS No.—
Chemical FormulaC38H52N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 2 structure
2
阿扎那韦杂质2Atazanavir Impurity 2
Atazanavir Impurity 2
CAS No.198904-34-6
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 3 structure
3
阿扎那韦杂质3Atazanavir Impurity 3
Atazanavir Impurity 3
CAS No.—
Chemical FormulaC37H50N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 4 structure
4
阿扎那韦杂质4Atazanavir Impurity 4
Atazanavir Impurity 4
CAS No.—
Chemical FormulaC42H46N6O4
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 6 (4R,5S-Diasteroisomer of DIBOC) structure
6
阿扎那韦杂质24Atazanavir Impurity 6 (4R,5S-Diasteroisomer of DIBOC)
Atazanavir Impurity 6 (4R,5S-Diasteroisomer of DIBOC)
CAS No.1006868-81-0
Chemical FormulaC32H42N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 7 structure
7
阿扎那韦杂质25Atazanavir Impurity 7
Atazanavir Impurity 7
CAS No.1192224-26-2
Chemical FormulaC36H50N6O5
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 8 structure
8
阿扎那韦杂质8Atazanavir Impurity 8
Atazanavir Impurity 8
CAS No.1028634-76-5
Chemical FormulaC37H50N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 9 (4R,5R-Diasteroisomer of DIBOC) structure
9
阿扎那韦杂质9Atazanavir Impurity 9 (4R,5R-Diasteroisomer of DIBOC)
Atazanavir Impurity 9 (4R,5R-Diasteroisomer of DIBOC)
CAS No.—
Chemical FormulaC32H42N4O5
Purity>95%询价On request
10mg25mg50mg100mg
rac-Atazanavir Impurity 9 structure
9
阿扎那韦杂质9rac-Atazanavir Impurity 9
rac-Atazanavir Impurity 9
CAS No.—
Chemical FormulaC32H42N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 10 (4S,5R-Diasteroisomer of DIBOC) structure
10
阿扎那韦杂质10Atazanavir Impurity 10 (4S,5R-Diasteroisomer of DIBOC)
Atazanavir Impurity 10 (4S,5R-Diasteroisomer of DIBOC)
CAS No.—
Chemical FormulaC32H42N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 11 structure
11
阿扎那韦杂质11Atazanavir Impurity 11
Atazanavir Impurity 11
CAS No.—
Chemical FormulaC17H27N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 12 structure
12
阿扎那韦杂质40Atazanavir Impurity 12
Atazanavir Impurity 12
CAS No.198904-84-6
Chemical FormulaC17H19N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 13 structure
13
阿扎那韦杂质13Atazanavir Impurity 13
Atazanavir Impurity 13
CAS No.—
Chemical FormulaC12H11N3
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 14 structure
14
阿扎那韦杂质14Atazanavir Impurity 14
Atazanavir Impurity 14
CAS No.—
Chemical FormulaC12H19N3
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 17 structure
17
阿扎那韦杂质20Atazanavir Impurity 17
Atazanavir Impurity 17
CAS No.98760-08-8
Chemical FormulaC15H21NO3
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 18 structure
18
阿扎那韦杂质18Atazanavir Impurity 18
Atazanavir Impurity 18
CAS No.156474-22-5
Chemical FormulaC42H46N6O4
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 19 structure
19
阿扎那韦杂质19Atazanavir Impurity 19
Atazanavir Impurity 19
CAS No.198904-85-7
Chemical FormulaC17H21N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 20 structure
20
阿扎那韦杂质20Atazanavir Impurity 20
Atazanavir Impurity 20
CAS No.102123-74-0
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 21 structure
21
阿扎那韦杂质21Atazanavir Impurity 21
Atazanavir Impurity 21
CAS No.98737-29-2
Chemical FormulaC24H29NO11
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 22 structure
22
阿扎那韦杂质22Atazanavir Impurity 22
Atazanavir Impurity 22
CAS No.99113-35-6
Chemical FormulaC32H42N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 23 structure
23
阿扎那韦杂质23Atazanavir Impurity 23
Atazanavir Impurity 23
CAS No.149451-80-9
Chemical FormulaC32H42N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 24 structure
24
阿扎那韦杂质47Atazanavir Impurity 24
Atazanavir Impurity 24
CAS No.156474-21-4
Chemical FormulaC15H21NO3
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 25 structure
25
阿扎那韦杂质25Atazanavir Impurity 25
Atazanavir Impurity 25
CAS No.869285-68-7
Chemical Formula—
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 28 structure
28
阿扎那韦杂质28Atazanavir Impurity 28
Atazanavir Impurity 28
CAS No.2307732-33-6
Chemical FormulaC17H27N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 33 structure
33
阿扎那韦杂质33Atazanavir Impurity 33
Atazanavir Impurity 33
CAS No.857904-03-1
Chemical FormulaC35H47N5O6
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 39 structure
39
阿扎那韦杂质39Atazanavir Impurity 39
Atazanavir Impurity 39
CAS No.26782-71-8
Chemical FormulaC6H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 41 structure
41
阿扎那韦杂质41Atazanavir Impurity 41
Atazanavir Impurity 41
CAS No.765254-57-7
Chemical FormulaC30H39N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 45 structure
45
阿扎那韦杂质45Atazanavir Impurity 45
Atazanavir Impurity 45
CAS No.1292296-13-9
Chemical FormulaC37H48N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 46 structure
46
阿扎那韦杂质46Atazanavir Impurity 46
Atazanavir Impurity 46
CAS No.15761-38-3
Chemical FormulaC8H15NO4
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 48 structure
48
阿扎那韦杂质48Atazanavir Impurity 48
Atazanavir Impurity 48
CAS No.1185296-42-7
Chemical FormulaC9H14F3NO4
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 51 structure
51
阿扎那韦杂质51Atazanavir Impurity 51
Atazanavir Impurity 51
CAS No.13734-36-6
Chemical FormulaC8H15NO4
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 52 structure
52
阿扎那韦杂质52Atazanavir Impurity 52
Atazanavir Impurity 52
CAS No.3744-87-4
Chemical FormulaC8H15NO4
Purity>95%询价On request
10mg25mg50mg100mg
Atazanavir Impurity 15-d9 structure
15-D9
阿扎那韦杂质15-d9Atazanavir Impurity 15-d9
Atazanavir Impurity 15-d9
CAS No.1092539-97-3
Chemical FormulaC8H6D9NO4
Purity>95%询价On request
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

阿扎那韦 —— 研究文献与合成路线Atazanavir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 阿扎那韦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Atazanavir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Determination of genotoxic impurity in atazanavir sulphate drug substance by LC-MS
    K GB, K BMK, N S, et al. · Journal of pharmaceutical and biomedical analysis · 2017 · 被引 11cited 11
  2. Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate
    Chitturi SR, Somannavar YS, Peruri BG, et al. · Journal of pharmaceutical and biomedical analysis · 2011 · 被引 6cited 6
  3. Simultaneous Determination of Impurities of Atazanavir and Ritonavir in Tablet Dosage Form by Using Reversed-Phase Ultra Performance Liquid Chromatographic Method
    Mantripragada MKVVN, Rao SV, Nutulapati VVS, et al. · Journal of chromatographic science · 2018 · 被引 3cited 3
  4. Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry
    Phung N, Kuncze K, Okochi H, et al. · Rapid communications in mass spectrometry : RCM · 2018 · 被引 12cited 12
  5. Trace Level Determination of Mesityl Oxide and Diacetone Alcohol in Atazanavir Sulfate Drug Substance by a Gas Chromatography Method
    Raju KV, Pavan Kumar KS, Siva Krishna N, et al. · Scientia pharmaceutica · 2016

合成与制备工艺专利Synthesis & process patents

  1. DRY PROCESSING OF ATAZANAVIR
    MEERGANS DOMINIQUE, STEFAN RALPH · 公开号 WO2012041488WO2012041488 · 2012
  2. PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS
    KIM SOOJIN, LOTZ BRUCE T, MALLEY MARY F, GOUGOUTAS JACK Z, et al. · 公开号 US2011124689US2011124689 · 2011
  3. PROCESS FOR THE PREPARATION OF ATAZANAVIR SULFATE SUBSTANTIALLY FREE OF DIASTEREOMERS
    MAHAKAL KUMODINI KASHINATH, SINGH GURVINDER PAL, RAY PURNA CHANDRA · 公开号 WO2011107843WO2011107843 · 2011
  4. Process for preparing atazanavir bisulfate and novel forms
    LOTZ BRUCE T, GOUGOUTAS JACK Z, DAVIDOVICH MARTHA, MALLEY MARY F, et al. · 公开号 AU2010201538AU2010201538 · 2010
  5. Process for Synthesizing Atazanavir
    CHEN WEIPING · 公开号 US2009270499US2009270499 · 2009

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

阿扎那韦 杂质谱研究要点Atazanavir — impurity profiling notes

下面这些是拿到 阿扎那韦 的 52 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 52 impurity entries for Atazanavir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances